Literature DB >> 35670774

The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer.

Goutam Chakraborty1,2, Subhiksha Nandakumar3,4, Rahim Hirani2, Bastien Nguyen3,4, Konrad H Stopsack2, Christoph Kreitzer3,4, Sai Harisha Rajanala2, Romina Ghale2, Ying Z Mazzu2, Naga Vara Kishore Pillarsetty5, Gwo-Shu Mary Lee6, Howard I Scher2,7, Michael J Morris2, Tiffany Traina2, Pedram Razavi2, Wassim Abida2, Jeremy C Durack5, Stephen B Solomon5, Matthew G Vander Heiden8, Lorelei A Mucci9, Andreas G Wibmer5, Nikolaus Schultz3,4,10, Philip W Kantoff2.   

Abstract

PURPOSE: Oncogenic alterations of the PI3K/AKT pathway occur in >40% of patients with metastatic castration-resistant prostate cancer, predominantly via PTEN loss. The significance of other PI3K pathway components in prostate cancer is largely unknown. EXPERIMENTAL
DESIGN: Patients in this study underwent tumor sequencing using the MSK-IMPACT clinical assay to capture single-nucleotide variants, insertions, and deletions; copy-number alterations; and structural rearrangements, or were profiled through The Cancer Genome Atlas. The association between PIK3R1 alteration/expression and survival was evaluated using univariable and multivariable Cox proportional-hazards regression models. We used the siRNA-based knockdown of PIK3R1 for functional studies. FDG-PET/CT examinations were performed with a hybrid positron emission tomography (PET)/CT scanner for some prostate cancer patients in the MSK-IMPACT cohort.
RESULTS: Analyzing 1,417 human prostate cancers, we found a significant enrichment of PIK3R1 alterations in metastatic cancers compared with primary cancers. PIK3R1 alterations or reduced mRNA expression tended to be associated with worse clinical outcomes in prostate cancer, particularly in primary disease, as well as in breast, gastric, and several other cancers. In prostate cancer cell lines, PIK3R1 knockdown resulted in increased cell proliferation and AKT activity, including insulin-stimulated AKT activity. In cell lines and organoids, PIK3R1 loss/mutation was associated with increased sensitivity to AKT inhibitors. PIK3R1-altered patient prostate tumors had increased uptake of the glucose analogue 18F-fluorodeoxyglucose in PET imaging, suggesting increased glycolysis.
CONCLUSIONS: Our findings describe a novel genomic feature in metastatic prostate cancer and suggest that PIK3R1 alteration may be a key event for insulin-PI3K-glycolytic pathway regulation in prostate cancer. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35670774      PMCID: PMC9438279          DOI: 10.1158/1078-0432.CCR-21-4272

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  64 in total

1.  PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.

Authors:  Lauren M Thorpe; Jennifer M Spangle; Carolynn E Ohlson; Hailing Cheng; Thomas M Roberts; Lewis C Cantley; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

Review 2.  From receptor to transporter: insulin signalling to glucose transport.

Authors:  G D Holman; M Kasuga
Journal:  Diabetologia       Date:  1997-09       Impact factor: 10.122

Review 3.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

Review 4.  Classes of phosphoinositide 3-kinases at a glance.

Authors:  Steve Jean; Amy A Kiger
Journal:  J Cell Sci       Date:  2014-03-01       Impact factor: 5.285

Review 5.  Molecular imaging of prostate cancer.

Authors:  Josef J Fox; Heiko Schöder; Steven M Larson
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

6.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors:  David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal:  Cancer Cell       Date:  2011-05-27       Impact factor: 31.743

7.  Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.

Authors:  Niamh M Keegan; Samantha E Vasselman; Ethan S Barnett; Barbara Nweji; Emily A Carbone; Alexander Blum; Michael J Morris; Dana E Rathkopf; Susan F Slovin; Daniel C Danila; Karen A Autio; Howard I Scher; Philip W Kantoff; Wassim Abida; Konrad H Stopsack
Journal:  Prostate       Date:  2022-05-10       Impact factor: 4.012

8.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

9.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

10.  Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.

Authors:  Yun Ye; Su-Liang Li; Sheng-Yu Wang
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.